Skip to main content
Premium Trial:

Request an Annual Quote

RareCyte Secures $24M to Advance Spatial Biology Platform, Expand Globally

NEW YORK – Life science company RareCyte said on Thursday that it completed $24 million in financing from both new and existing investors.

Arboretum Ventures led the financing, along with several other new investors, including F-Prime Capital, Logos Capital, and Agilent Technologies. Existing investors HealthQuest Capital, 5AM Ventures, and RareCyte founder Ron Seubert also participated.

RareCyte anticipates that the financing will help further develop its proprietary Orion Spatial Biology platform, designed for high-resolution spatial analysis of tissue samples.

The platform shipped to early adopter sites last year and the company stated that it is increasing production at its Seattle headquarters.

"We are thrilled to have Arboretum Ventures lead this new funding round," Joe Victor, RareCyte's president and CEO, said in a statement.

"This funding will allow RareCyte to fast-track important new applications and capabilities for our Orion spatial biology platform," he added, "and accelerate the expansion of global sales and marketing channels for all of our products including our latest tissue and liquid biopsy applications."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.